Brigatinib

Abbreviation
BGB
Disease(s)
non-small cell lung cancer (NSCLC)
Background
.pdf
Patent oppositions filed in
Argentina

Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) used to treat metastatic lung cancer.

This drug is missing the following documents, can you help us by contributing something?

Oppositions

Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
Argentina21-10-2019CILFAPre-GrantUnder ExaminationFormulationsAR111169A1View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top